A Phase II Open-label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African American and Caucasian Men With Metastatic Castrate-resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms Abi Race
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 08 Aug 2017 Planned End Date changed from 1 Mar 2018 to 1 Oct 2018.
- 08 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2018.